Latest news with #CannabinoidHyperemesisSyndrome
USA Today
12-08-2025
- Health
- USA Today
Trump may reclassify marijuana as less dangerous drug. Is that a good thing?
President Donald Trump is looking to reclassify marijuana as a less dangerous drug under federal law. Speaking to reporters at the White House briefing room Aug. 11, Trump said a decision could come within the next couple of weeks. Since 1970, the federal government has classified marijuana as a Schedule I drug, which is defined as highly dangerous, addictive and without medical use. In 2024, the Drug Enforcement Administration proposed a rule to transfer marijuana to Schedule III, which includes drugs like ketamine and testosterone. Trump said the decision is complicated, weighing the benefits of marijuana use for medical reasons against potential societal impacts. "Some people like it, some people hate it. Some people hate the whole concept of marijuana," he said. Trump hints at marijuana policy shift: What to know about THC For the most part, the move would be good for science, research and medicine, said Raphael Cuomo, biomedical scientist and professor of medicine at the University of California San Diego School of Medicine. 'Rescheduling would make it easier to study potential benefits and harms across conditions, which could improve dosing guidance and drug interaction data in oncology, pain and palliative care,' he said. It would also likely improve quality control for cannabinoids that are approved by the Food and Drug Administration and speed up high-quality clinical trials to improve product standardization and 'answer clinical questions that matter to patients,' Cuomo said. But it's not all good. Cuomo said reclassifying marijuana could be perceived as a 'safety endorsement" as rates of heavy and daily use continue to climb. In 2022, marijuana surpassed high-frequency drinking for the first time, according to a 2024 study published in the journal Addiction. An estimated 17.7 million people used marijuana daily or near-daily, compared to 14.7 million daily or near-daily drinkers. Inflation? Not in the cannabis market. Here's why weed is so cheap. From 1992 to 2022, the per capita rate of reporting daily or near-daily marijuana use increased 15-fold, the study found. About 40% of cannabis users reported doing it daily or near daily. Research has shown long-term or heavy cannabis use can cause brain and mental health effects such as memory problems, psychotic disorders and psychosis, according to the Colorado Department of Public Health and Environment. It can also irritate the lungs, leading to a daily cough, bronchitis, mucus and wheezing, and may carry some cardiovascular risks, according to recent research. Some people who use cannabis heavily can start vomiting without being able to stop, a condition called Cannabinoid Hyperemesis Syndrome, which can be reversed by stopping marijuana use. If the administration decides to reclassify marijuana, Cuomo said officials should also focus public messaging efforts to include warnings for youth, pregnancy, driving and individuals with a history of psychosis. "Risk perception often moves faster than policy," he said. Contributing: Sarah D. Wire, USA TODAY; Reuters. Adrianna Rodriguez can be reached at adrodriguez@
Cision Canada
13-06-2025
- Health
- Cision Canada
AURORA CANNABIS CHS CLASS ACTION CERTIFIED Français
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. . Sotos Class Actions 55 University Avenue, Suite 600 Toronto, ON M5J 2H7 [email protected] 1-877-294-9747 (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
Yahoo
09-06-2025
- Health
- Yahoo
AURORA CANNABIS CHS CLASS ACTION CERTIFIED
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. More information about the class proceeding, including the Plaintiff's Fresh as Amended Statement of Claim, is available on Class Counsel's website: For further information, or if you have been diagnosed with CHS, please contact Class Counsel: Sotos Class Actions 55 University Avenue, Suite 600Toronto, ON M5J 2H7auroracannabisclassaction@ (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at mwaddell@ SOURCE Sotos Class Actions View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
09-06-2025
- Health
- Cision Canada
AURORA CANNABIS CHS CLASS ACTION CERTIFIED
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. . Sotos Class Actions 55 University Avenue, Suite 600 Toronto, ON M5J 2H7 [email protected] 1-877-294-9747 (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
